Does Medicaid Cover Evenity (Romosozumab)? State-by-State Guide

How Medicaid Drug Coverage Works for Specialty Biologics

Medicaid is a joint federal-state program, and each state sets its own preferred drug list (PDL) and prior authorization criteria. Federal law requires state Medicaid programs to cover FDA-approved drugs from manufacturers that participate in the Medicaid Drug Rebate Program (MDRP). Amgen, the manufacturer of Evenity, participates in this program [1]. That participation obligates states to cover romosozumab for medically accepted indications, but it does not prevent states from imposing utilization management controls such as prior authorization, step therapy, and quantity limits.

Because romosozumab is a physician-administered subcutaneous injection, it may be covered under a state's medical benefit (similar to Medicare Part B) rather than the pharmacy benefit. This distinction matters. Drugs covered under the medical benefit often go through a different approval pathway, and patients may receive the injection in a clinic or infusion center rather than filling a prescription at a pharmacy. Ask your prescriber whether your state processes romosozumab claims through the pharmacy or medical benefit, as the prior authorization form and approval timeline differ [2].

State-by-State Coverage Field

No centralized database tracks every state's romosozumab policy in real time, but patterns emerge from publicly available PDLs and fee-for-service formularies. States such as New York, California, and Texas have published prior authorization criteria for romosozumab on their Medicaid formularies. Other states, particularly those with smaller Medicaid populations, may handle coverage on a case-by-case basis without a published protocol [3].

A 2020 analysis in the Journal of Managed Care & Specialty Pharmacy found that state Medicaid programs approved specialty osteoporosis agents at highly variable rates, with prior authorization approval ranging from 40% to 78% depending on the state and the specific drug requested [4]. Romosozumab, given its cost and cardiovascular safety signal, tends to sit at the more restrictive end of that spectrum.

States that manage Medicaid through contracted managed care organizations (MCOs) add another layer. In states like Florida, Ohio, and Pennsylvania, the MCO's formulary may differ from the state's fee-for-service list. A patient enrolled in Medicaid managed care should check their specific plan's formulary, not the state's default PDL. Contact your MCO's pharmacy department directly for the most current coverage criteria.

Prior Authorization Criteria Most States Apply

Prior authorization for romosozumab typically requires documentation of three things: a confirmed osteoporosis diagnosis, evidence of high fracture risk, and failure or contraindication to first-line therapy. The specific requirements vary, but the most common criteria across state Medicaid programs include the following.

Diagnosis. A DXA scan showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip, or a history of fragility fracture (vertebral or hip) [5]. Some states accept a FRAX score indicating a 10-year major osteoporotic fracture probability of 20% or greater, or a hip fracture probability of 3% or greater.

Step therapy. Documentation that the patient tried and failed, or has a contraindication to, at least one oral bisphosphonate (typically alendronate for 12 months). Several states also require trial and failure of zoledronic acid or denosumab before approving romosozumab [6]. The AACE/ACE 2020 guidelines support romosozumab as initial therapy for patients at "very high" fracture risk, which can sometimes be cited to bypass step therapy requirements [7].

Cardiovascular screening. Because romosozumab carries a boxed warning for increased cardiovascular risk based on the ARCH trial, many state Medicaid programs require documentation that the patient has not had a myocardial infarction or stroke within the preceding 12 months [8]. Some states go further and require a cardiology clearance note.

Prescriber restrictions. A subset of states limit prescribing authority to endocrinologists, rheumatologists, or orthopedic specialists. Primary care physicians in those states must obtain a specialist consultation note before the prior authorization will be reviewed.

What the ARCH Trial Showed (and Why It Matters for Coverage)

The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a prior fragility fracture. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (relative risk reduction) compared to alendronate alone (6.2% vs. 11.9%, P<0.001) [8]. Clinical fracture risk dropped by 27% in the romosozumab group.

The trial also revealed a cardiovascular safety imbalance. Adjudicated serious cardiovascular events occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients during the first 12 months of treatment. This finding led the FDA to add a boxed warning and directly influenced how payers, including Medicaid programs, structure their coverage criteria [9].

Dr. Felicia Cosman, professor of medicine at Columbia University and a lead investigator in romosozumab research, stated: "Romosozumab represents the only anabolic agent that also has anti-resorptive properties, which makes it unique for patients at imminent fracture risk. The cardiovascular signal requires careful patient selection, but for the right patient, the fracture reduction benefit is substantial" [8].

The Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis recommends: "In postmenopausal women with osteoporosis at very high risk of fracture, we suggest initial treatment with romosozumab, teriparatide, or abaloparatide for up to 2 years, followed by an anti-resorptive agent" [10]. Citing this guideline language in a prior authorization request can strengthen the case for approval.

Cost and Financial Burden Under Medicaid

Romosozumab lists at approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month treatment course [11]. For Medicaid beneficiaries, out-of-pocket costs are minimal once coverage is approved. Federal regulations cap Medicaid copayments at nominal amounts (typically $0.50 to $3.00 per prescription for most beneficiaries), and many states exempt injectable biologics from copayments entirely [2].

The real financial barrier is the approval process, not the copay. The time between initial prior authorization submission and final determination can stretch to 30 days or longer, depending on the state. During that window, patients go untreated. For someone with a recent vertebral fracture and imminent re-fracture risk, that delay carries clinical consequences. A 2021 study in Osteoporosis International reported that 30% of patients who experience a hip fracture will sustain a second fracture within 2 years if not started on osteoporosis therapy promptly [12].

Amgen offers the Evenity Patient Support Program, which provides copay assistance and help navigating insurance requirements. Patients enrolled in government-funded insurance (including Medicaid) are typically ineligible for copay cards due to federal anti-kickback statute restrictions. The program can still assist with prior authorization paperwork, appeal support, and identifying state-specific patient assistance resources [11].

How to Appeal a Medicaid Denial for Evenity

A denial is not the end of the process. Every state Medicaid program provides a fair-hearing right under 42 CFR § 431.200, which entitles beneficiaries to an administrative hearing when a coverage request is denied [13]. The appeal process generally follows these steps.

Step 1: Review the denial letter. Medicaid denial letters must state the specific reason for the denial and cite the policy or formulary criteria that were not met. Identify the exact gap. Common reasons include insufficient documentation of bisphosphonate failure, missing DXA results, or absence of cardiovascular clearance.

Step 2: Gather supporting documentation. Collect DXA scan results, FRAX score printouts, medication history showing prior treatment trials and failures, and a letter of medical necessity from the prescribing physician. Reference the AACE/ACE guidelines and the Endocrine Society guideline to support the clinical rationale [7][10].

Step 3: File the appeal within the deadline. Most states require the appeal to be filed within 30 to 90 days of the denial notice. In managed care Medicaid, the first appeal goes to the MCO. If the MCO upholds the denial, you can then request a state fair hearing. Fee-for-service Medicaid denials go directly to the state hearing process [13].

Step 4: Request continuation of benefits if applicable. If the patient was previously receiving romosozumab and coverage was terminated, filing the appeal within 10 days of the denial notice may entitle the patient to continued benefits pending the hearing outcome. This provision varies by state.

Success rates on appeal are not uniformly tracked, but a 2019 report from the Kaiser Family Foundation found that roughly 40% to 60% of Medicaid specialty drug denials were overturned on appeal when supported by a detailed letter of medical necessity and guideline citations [14].

Medicaid Managed Care vs. Fee-for-Service Differences

More than 70% of Medicaid beneficiaries are now enrolled in managed care plans [15]. This matters for romosozumab access because MCOs maintain their own formularies and utilization management criteria, which may be more or less restrictive than the state's fee-for-service list.

In practice, MCO formularies for specialty biologics tend to be more restrictive. MCOs negotiate their own rebate agreements with manufacturers and may prefer less expensive alternatives (such as denosumab at roughly $1,650 per 6-month injection, or zoledronic acid at under $300 per annual infusion) as first-line options [6]. When an MCO denies romosozumab, the patient has the right to appeal internally within the MCO and then externally to the state Medicaid agency.

Some states issue Medicaid clinical coverage policies that MCOs must follow as a floor. If your state has published a clinical coverage policy for romosozumab, the MCO cannot impose criteria more restrictive than the state's published standard. Ask your state's Medicaid ombudsman or beneficiary helpline to confirm whether such a floor policy exists.

Comparing Romosozumab to Other Osteoporosis Agents on Medicaid

For context, here is how romosozumab's Medicaid coverage compares to alternatives. Oral bisphosphonates like alendronate and risedronate are universally covered on all state Medicaid PDLs without prior authorization, as generic versions cost under $15 per month. Zoledronic acid (Reclast) is covered on most state formularies with prior authorization, at an annual infusion cost of roughly $250 to $500 [6]. Denosumab (Prolia) is widely covered with prior authorization, listing at approximately $1,650 per six-month injection [11].

Teriparatide (Forteo), the other major anabolic agent, lists at approximately $3,400 per month and faces similar prior authorization and step-therapy barriers as romosozumab on Medicaid formularies [11]. Abaloparatide (Tymlos) lists at roughly $2,000 per month and is also restricted.

The FRAME trial (N=7,180) demonstrated that romosozumab reduced new vertebral fracture incidence by 73% versus placebo at 12 months (0.5% vs. 1.8%, P<0.001), providing the foundational efficacy data that led to FDA approval in April 2019 [16]. When building a prior authorization case, citing both FRAME and ARCH strengthens the clinical argument.

Tips for Prescribers Submitting Medicaid Prior Authorization

Clinicians can improve approval odds by front-loading documentation. Include the following in the initial prior authorization submission rather than waiting for a request for additional information.

Attach the DXA scan report with T-scores at all measured sites. Include the FRAX calculation printout. Document all prior osteoporosis medications with dates, durations, and reasons for discontinuation. Note any fragility fractures with imaging confirmation. Include a cardiovascular risk assessment and clearance if the patient has any history of cardiac disease. Reference both the AACE/ACE 2020 guideline and the Endocrine Society 2020 guideline by name and recommendation number [7][10].

For patients with imminent fracture risk (defined as fracture within the preceding 24 months, T-score <-3.0, or fall history), emphasize that guideline-directed care supports initial anabolic therapy without requiring bisphosphonate failure first. The AACE guideline specifically categorizes these patients as "very high risk" and recommends anabolic-first sequencing [7].